JESSICA LUERA: Open Payments
NPI 1255811238 · SAN BERNARDINO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$625 in 29 payments from 7 companies in 2025. Trend: 2023 $57 · 2024 $348 · 2025 $625
Food & beverage: $625
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 11 | $260 |
| Alkermes, Inc. | 5 | $118 |
| Janssen Pharmaceuticals, Inc | 4 | $75 |
| Otsuka America Pharmaceutical, Inc. | 3 | $58 |
| Teva Pharmaceuticals USA, Inc. | 3 | $48 |
| Luye Pharma (USA) Ltd. | 2 | $38 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $28 |
Products named: INGREZZA, ARISTADA, INVEGA SUSTENNA, ABILIFY ASIMTUFII, AUSTEDO XR, ERZOFRI EXTENDED-RELEASE, CAPLYTA, VIVITROL.
Industry payments across CA — which companies pay providers there.
